Abstract: This disclosure relates to methods of preparing re-usable and dry-able cartridges comprising matrices comprising a detection molecule such as an antibody, for detection or enrichment of an analyte in a sample, such as an antigen recognized by an antibody. In some embodiments, the cartridge comprises a tube or well that holds the matrix. In some embodiments, the matrix or associated cartridges may be stored wet or dry. The disclosure also relates to the cartridges and methods of their use.

Abstract: Disclosed herein are compositions and methods for the treatment of systemic lupus erythematosus using anti-CD20/anti-CD3 bispecific antibodies, such as mosunetuzumab.

Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.

Abstract: Embodiments disclosed herein generally relate to connected machine learning models with joint training for lesion detection. Particularly, aspects of the present disclosure are directed to accessing a three-dimensional magnetic resonance imaging (MRI) image, wherein the three-dimensional MRI image depicts a region of a brain of a subject, wherein the region of the brain includes at least a first type of lesions and a second type of lesions; inputting the three-dimensional MRI image into a machine-learning model comprising a first convolutional neural network and a second convolutional neural network; generating a first segmentation mask for the first type of lesions using the first convolutional neural network that takes as input the three-dimensional MRI image; generating a second segmentation mask for the second type of lesions using the second convolutional neural network that takes as input the three-dimensional MRI image; and outputting the first segmentation mask and the second segmentation mask.

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

Abstract: The presently disclosed subject matter relates to “Randomized Configuration Targeted Integration” (also referred to herein as “Randomized Chain Targeted Integration”) (RCTI) strategies for the generation and identification of host cells capable of expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes and other difficult to express molecules.

Abstract: The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

Abstract: The disclosure relates to methods for handling and supplementation of cell culture medium to improve process performance in eukaryotic recombinant expression systems.

Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.

Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma and diffuse large B cell lymphoma) using immunoconjugates comprising anti-CD79b antibodies in combination with a Bcl-2 inhibitor (such as venetoclax) and an anti-CD20 antibody (such as obinutuzumab or rituximab).

Abstract: The present disclosure relates to compounds comprising a VHL ligand moiety and to methods of using such compounds as ligands of VHL. The present disclosure further relates to the use of the compounds described herein, or pharmaceutical compositions thereof, to prevent and/or treat a range of diseases, disorders, and conditions.

Abstract: Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8+ T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.

Abstract: A method of preparing a prefilled syringe is disclosed that includes obtaining a syringe barrel and a needle adaptor cap assembled on the tip of the syringe barrel, wherein the needle adaptor cap has a rubber element tightly sealing the orifice of the tip of the syringe barrel and the syringe barrel together with the needle adaptor cap assembled on the tip of the syringe barrel is sterilized by a first sterilizing. Filling a drug substance into an interior of the syringe barrel and sealing the interior of the syringe barrel. Packaging the syringe barrel with a rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel. Providing a second external surface sterilizing of the packaged syringe barrel with the rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel.

Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).

Abstract: Provided herein are solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one and methods of their use in the treatment of cancer.

Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.

Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.